Clay Siegall Looks To Make Great Leaps Forward For Science
Clay Siegall has been one of the most respected scientists in the U.S. for a number of years after bringing the skills he developed at the University of Maryland and George Washington University to keep abreast of the latest changes in the scientific and medical fields. Dr. Siegall is always looking to develop his knowledge and skills by keeping up with the latest work completed by his own Seattle genetics company and leading scientists around the world.
Dr. Siegall is always looking to keep up to date with the latest breakthroughs that are changing the face of the medical and scientific industries, including a great deal of work completed to maintain his knowledge of the breakthroughs being made in terms of the ever changing space race; as an expert in medical research Clay Siegall is interested in how the effects of space can damage the body of astronauts and how these changes can be reversed. One area of interest for Clay Siegall is in the vision problems astronauts suffer after prolonged periods in space. Travel in space is a recurring theme in the interests of Clay Siegall as he is interested in the work of the SpaceX company who are looking to send two space tourists on a journey around the dark side of the Moon.
In terms of his career, Clay Siegall has been a major part of the cancer research community for many years and spent the years 1988 through 1991 working with the National Institutes of Health before moving to work at the National Cancer Institute until 1997. Dr. Siegall made his name as a scientist and medical researcher within the cancer research community and continues to play a key role in the development of new drugs and treatments for cancer patients.
As the founder of Seattle Genetics Clay Siegall has formed a specific plan for the company to move forward in the development of different drugs for cancer patients; specifically, Seattle genetics has been leading the development and research into antibody-drug conjugates that have included over 30 licenses and more than $350 million in funding for Clay Siegall’s company.